Track topics on Twitter Track topics that are important to you
GENEVA, May 5, 2017 /PRNewswire/ --
"Immune checkpoint inhibitors such as nivolumab and pembrolizumab significantly improve overall survival in some - but not all - patients with non-small cell lung cancer (NSCLC)," said Dr Marcello Tiseo, Coordinator of DMT Thoracic Oncology, University Hospital of Parma, Italy. "Researchers are looking for a predictive biomarker to select patients that will benefit from this treatment to avoid unnecessary toxicity and a waste of resources in patients who will not respond."
He continued: "PD-L1 expression in a biopsy of tumour tissue is now used to select patients but it is not completely accurate, possibly because it does not reflect the evolving immune response. Biomarkers in the blood are easier to obtain and may be better indicators of immune response."
This study assessed the ability of white blood cell counts to predict whether lung cancer patients responded to treatment with nivolumab. The study included 54 patients with NSCLC who received nivolumab at a dose of 3 mg/kg every 14 days.
The researchers found that white blood cell counts at baseline and during therapy did predict whether lung cancer patients would respond to nivolumab treatment. A greater number and concentration of natural killer cells at baseline was associated with response to nivolumab, as was an increase in the number of natural killer cells during treatment.
ESMO is the leading professional organisation for medical oncology, with over 15,000 members representing oncology professionals from over 130 countries worldwide.
ELCC Press Office
SOURCE European Society for Medical Oncology (ESMO)NEXT ARTICLE
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...